The ideal prevention, treatment and control response to fatty liver has three main principles: early intervention, long-term treatment and individualized comprehensive treatment, which requires objective assessment of the effectiveness and safety issues of short-term and long-term drug therapy. Adequate clinical practice has proven that drugs that solely target a particular pathogenesis are difficult to cure fatty liver and its complications unless the root causes of fatty liver disease, namely caloric excess and alcohol abuse that trigger obesity, are addressed at an early stage. For patients with only early symptoms of fatty liver, a balanced diet with seven or eight saturated meals and regular exercise is not even necessary to take medication at all. When the liver has already shown obvious symptoms of inflammation and liver fibrosis, the effect of etiologic treatment will no longer be ideal, and even if one succeeds in losing weight and insists on abstaining from alcohol, it is difficult to guarantee the complete recovery of patients with fatty liver at this stage. At this point, in addition to cutting off the root cause of the disease, medication is also essential, and the most critical thing is to repair the damaged liver cells and cell membranes. Indiscriminate use of medication often leads to the deterioration of fatty liver. There are also three major principles to follow in the use of medication for fatty liver. First, it needs to be combined with the treatment of other diseases Because the harm of fat toxicity of obesity and alcohol is not limited to the liver, so the treatment of fatty liver needs to have an overall treatment system that takes into account the liver and systemic diseases. At present, our patients need to strengthen the joint application of drugs targeting metabolic disorders and liver-protective drugs to prevent and treat fatty liver, especially non-alcoholic fatty liver, based on lifestyle changes of a therapeutic nature. This has been confirmed by large samples, long courses of treatment and randomized controlled clinical trials. At present, most patients with fatty liver belong to non-alcoholic fatty liver, the source of the disease is excessive obesity, so it is easy to “a fatty disease”. These patients need to take long-term control of metabolic disorders of a variety of drugs, such as antihypertensive drugs, lipid-lowering drugs, etc., in the process of drug use, the drug itself can lead to liver damage, that is, drug-related liver injury. Therefore, the addition of liver-protective drugs at the same time as medication can improve the effectiveness and safety of the underlying treatment. The choice of liver-protective drugs, with plant-derived ingredients, products with long-term clinical effectiveness verification and national certification is preferred. Third, you can’t just rely on drugs For patients with steatohepatitis and cirrhosis, drug therapy for metabolic syndrome is as important as anti-inflammatory and liver-protective drug therapy. Anti-inflammatory and hepatoprotective drugs are an indispensable part of the comprehensive treatment for patients with steatohepatitis and play an important role in the treatment selection, which can play an anti-inflammatory, hepatoprotective and hepatic fibrosis prevention role. In addition, non-pharmacologic treatment with lifestyle changes is equally important as pharmacologic treatment. If medication does not significantly improve the condition, prompt consideration should be given to bariatric surgery, liver transplantation, etc. Bariatric surgery is a more effective and safe way to treat both metabolic disorders and NAFLD, while liver transplantation is the only effective treatment for end-stage liver disease.